Alliance Pharma PLC

Alliance Pharma PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)59.80
  • Today's Change-0.80 / -1.32%
  • Shares traded750.98k
  • 1 Year change-47.91%
  • Beta0.7616
Data delayed at least 20 minutes, as of Jun 06 2023 16:37 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Alliance Pharma PLC is a United Kingdom-based international consumer healthcare company. The principal activity of the Company is to act as a holding company. The principal activity of the Company is the acquisition, marketing and distribution of consumer healthcare and pharmaceutical products. Its segments are strategic business units that represent different parts of the overall product portfolio, these being Consumer Healthcare brands and Prescription Medicines. Its Consumer Healthcare brands include Kelo-Cote franchise, Amberen, Nizoral, MacuShield, Aloclair, Vamousse, and other consumer healthcare brands. Its Prescription Medicines include Hydromol, Flamma Franchise, Forceval and other prescription medicines. Its products include Aloclair Plus Gel, Changmin, Fazol Cream, Hydromol Ointment, Kelo-Stretch Cream, and others. It holds the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are sold around the world in more than 100 countries.

  • Revenue in GBP (TTM)167.42m
  • Net income in GBP936.00k
  • Incorporated2001
  • Employees249.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Genovis AB10.45m3.14m252.53m37.0080.3820.0669.4024.170.64820.64822.162.600.8217----3,813,214.0024.7111.8627.2314.2269.4461.7930.0814.30----0.000.0010.0734.96-54.84--16.75--
Selvita SA79.41m5.39m259.33m847.0048.104.9919.823.271.531.5222.4814.710.773123.995.51464,081.905.49--6.95--66.57--7.10--1.319.900.4541--31.71--103.43------
Niox Group PLC31.30m14.10m264.70m92.0019.803.2314.168.460.03180.03630.07070.19520.33862.685.05340,217.4015.25-7.4216.49-9.2170.9374.0445.05-44.462.97--0.0121--12.19-7.53513.04---34.02--
DBV Technologies SA4.59m-78.84m288.81m226.00------62.92-1.67-1.670.0973-----------------------1,717.80-1,272.93---586.89-----49.38-10.6938.59------
Hyloris Pharmaceuticals SA2.54m-9.28m291.83m24.00--6.16--114.81-0.3954-0.39540.10851.970.0471--0.7924125,042.40-17.19-22.99-20.60-29.1596.8192.55-364.96-644.94----0.0158---4.6869.176.99---23.39--
Ultimovacs ASA0.00-12.04m295.17m24.00--9.58-----4.82-4.820.0012.300.00----0.00-30.14-25.92-32.89-27.77------------0.0118-------1.86--56.16--
Avacta Group Plc9.65m-39.54m305.64m133.00--16.00--31.66-0.1535-0.1520.03780.06940.13822.581.95---56.63---116.86--75.03---409.61--0.7967-2.510.7734--228.22---49.92------
MedCap AB (publ)82.27m8.70m326.71m368.0037.555.1521.423.977.947.9475.0457.830.85523.717.233,019,565.009.087.7011.5110.7147.8145.2610.628.461.928.990.28360.0021.28--21.87------
Alliance Pharma plc167.42m936.00k327.32m249.00417.931.1427.991.960.00150.00150.30840.53270.32172.904.70672,353.400.17982.640.19642.9560.7463.380.55918.351.735.370.323563.202.5810.50-87.21-49.62-25.785.94
Deva Holding AS211.65m54.98m347.77m2.92k6.332.095.731.647.277.2727.9822.040.71261.496.601,968,080.0018.5121.3332.8733.3754.1953.7225.9832.510.924715.280.47962.7792.1541.1116.2571.1858.49--
Philogen SpA20.43m-4.63m382.87m141.00--6.27--18.74-0.1324-0.13240.58392.420.18346.0311.98168,177.30-4.16-6.14-4.55-7.2659.0734.41-22.67-50.979.000.19950.1387--850.0417.9065.81--52.53--
Carbios SA60.30k-23.90m387.55m104.00--3.58--6,427.58-2.47-2.470.006211.160.0004--1.92673.08-15.30-9.39-16.59-10.23-1,531.43---39,630.00-1,258.36---15.140.2338---33.33-41.05-833.89--99.37--
Calliditas Therapeutics AB69.93m-29.08m405.84m181.00--8.38--5.80-7.35-7.3517.7110.980.60293.5516.309,259,775.00-25.07-27.85-29.58-30.9597.50---41.58-125.043.89-31.870.5589--250.07--17.59------
Northern Data AG14.11m-72.58m406.17m162.00--1.64--28.79-7.25-7.251.4112.06------101,094.80--20.18--33.1637.2050.93-514.4885.770.301-0.52520.25190.001,059.28485.60440.81------
Data as of Jun 06 2023. Currency figures normalised to Alliance Pharma PLC's reporting currency: UK Pound GBX

Institutional shareholders

45.73%Per cent of shares held by top holders
HolderShares% Held
Slater Investments Ltd.as of 21 Mar 202249.69m9.20%
Van Lanschot Kempen Investment Management NVas of 21 Mar 202239.39m7.30%
BlackRock Investment Management (UK) Ltd.as of 28 Sep 202226.35m4.88%
Investec Wealth & Investment Ltd.as of 21 Mar 202224.83m4.60%
Fidelity Management & Research Co. LLCas of 12 Dec 202223.29m4.31%
Rathbones Investment Management Ltd.as of 21 Mar 202219.53m3.62%
Polar Capital LLPas of 21 Mar 202219.10m3.54%
RBC Global Asset Management (UK) Ltd.as of 08 Jun 202216.55m3.06%
Artemis Investment Management LLPas of 23 Mar 202116.30m3.02%
Janus Henderson Investors UK Ltd.as of 02 Mar 202311.91m2.21%
More ▼
Data from 30 Sep 2022 - 28 Apr 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.